Houston's workforce is at a crossroads of industry challenges and AI opportunities

guest column

This Houston AI expert is calling the city's business leaders to step up when it comes to AI. Photo via Getty Images

Houston's industrial and energy landscapes are at a pivotal juncture. We're witnessing an undeniable gap in technical expertise that's hard to ignore. At the same time, there's a rising wave of artificial intelligence-driven solutions that could be the answer we've been searching for.

The expertise shortfall

Our city has always been the pulse of the energy and industrial sectors. We've grown, we've innovated, and we've set benchmarks for the world. But as we steer ahead, a pressing concern looms large: the dwindling pool of technical expertise. This isn't about not having enough hands-on deck; it's about not having the right hands to navigate our industries' intricate machinery and complex systems. Pipelines, refineries, renewable energy solutions – these are the cornerstones of Houston's legacy, and we need adept professionals to keep pushing boundaries.

AI: The game changer

But here's the thing: Houston isn't just the hub of traditional energy and industrial operations. We're sitting on a goldmine of data, real-world use cases, and the drive to innovate. Enter AI. It's not just tech jargon; it's a tool with untapped potential, waiting to be harnessed.

We have the industry foundation, the data reservoirs, and the prime use cases that make AI not just viable, but indispensable. Houston is uniquely positioned to lead this AI revolution. We're not just talking about implementing AI; we're talking about innovating with AI, tailoring it to our city's and our industry’s needs, and setting a precedent for the global stage. This is where the challenge meets opportunity. We have what it takes to mold AI solutions that can fill the expertise gap and propel our industries to new heights.

Houston's call to action

If there's any city poised to be the epicenter of AI, it's Houston. We've always been pioneers, and this is our chance to solidify our position as global leaders once again. Houston has everything: the industries, the data, the use cases, and most importantly, the ambition. The question isn't whether we can usher in an era of AI-enhanced operations; it's how swiftly we can do it.

Our city is on the brink of something monumental. It's time we leverage AI to not just bridge the expertise gap but to create an industrial future that's resilient, innovative, and unparalleled. So, to industry leaders, stakeholders, and visionaries, here's the pitch: Houston's at a crossroads, and the path we choose now will shape our legacy for decades. It's time we lean into AI, harness its potential, and ensure that our city remains the powerhouse it's always been.

However, this one question remains: Are you, this city's industry leaders, ready to redefine Houston's legacy in the face of an expertise challenge, or will you stick to the status quo and risk stagnation?


------

Marty Dytrych is the co-founder and CEO of Industrial Data Labs.

From Your Site Articles
Industrial Data Labs announced the close of its $1.5 million seed round of funding. Photo via Getty Images

Houston AI startup raises $1.5M seed round of funding

money moves

A Houston startup that's on a mission to transform and expedite data processing for its industrial clients has raised seed funding.

Industrial Data Labs announced this week that it's closed a $1.5 million seed round of funding. The company has created an applied artificial intelligence technology for the pipe, valve, fitting, and flange, or PVF, industry's inside sales team. The terms of the seed round were not disclosed.

"Our groundbreaking AI-Powered Inside Sales Copilot is transforming the way inside sales teams operate in the PVF industry," Marty Dytrych, co-founder and CEO of Industrial Data Labs, says in a news release. "By embedding our solution into existing BOM and MRO workflows, we empower teams to achieve unmatched efficiency, accuracy, and sales performance.”

Dytrych founded the company with COO Aaron deOliveira and CTO Tige Richardson in 2020. Per the release, Industrial Data Labs will use the funding to continue growing to continue delivering its "solutions that enhance efficiency and create new opportunities" within the PVF industry.

The company did not disclose its seed investors, but reported that Marshal Kushniruk is among the investors and is a member of the company's board of directors.

"Industrial Data Labs' innovative application of AI technology has the potential to bring significant transformation to the industrial sales landscape," Kushniruk says in the release. We are thrilled to support their mission and drive impactful change within the PVF industry.”

Mark Janzen is an early investor in Industrial Data Labs.

"Industrial Data Labs is at the forefront of Applied AI solutions in the industrial sector," he adds. "We believe their commitment to delivering unparalleled value to clients through their Inside Sales Copilot will have a lasting impact on the industry.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

5 must-read innovation headlines: Pharma giant considers Houston hub + more

Trending news

Editor's note: With May coming to a close, it's time to look back at the biggest innovation headlines for the second half of the month. Major moves were made in May, with NuScale Power entering the market, Persona AI inking a deal with Under Armour, and a pharma giant considering Houston for its next manufacturing hub. Here are the most-read InnovationMap stories published May 15-29, 2026:

1. Pharma giant considers Houston for $1 billion manufacturing campus

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub. According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

2. Modular nuclear reactor co. NuScale Power moves into Houston market

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

3. Persona AI teams with Under Armour to protect next-gen robots

Houston-based Persona AI has cemented a partnership with sportswear manufacturer Under Armour to provide materials to protect future robots operating in dangerous conditions. Through the partnership, Persona AI and Under Armour will launch a research initiative to explore whether advanced performance textiles can improve the durability and resilience of humanoid robots operating in harsh industrial environments.

4. Houston quantum energy chip startup emerges from stealth with $12M round

Houston-based Casimir has emerged from stealth with a $12 million seed round to commercialize its quantum energy chip. The round was led by Austin-based Scout Ventures. Lavrock Ventures, Cottonwood Technology, Capital Factory, American Deep Tech, and Tim Draper of Draper Associates also participated in the round. The oversubscribed round exceeded the company’s original $8 million target.

5. Global summit spotlights Houston's growing role in brain health, innovation

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. The summit, held June 9-10 at the Texas Medical Center's Helix Park, will bring together more than 500 executives, researchers, policymakers and innovators from around the world to discuss the global brain economy.

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”

View All Listings